April 26 Amgen Inc on Wednesday
reported higher-than-expected first-quarter profit as cost
controls helped offset a sharp drop in sales of Enbrel, its
blockbuster rheumatoid arthritis and psoriasis drug.
The world's largest biotechnology company said net profit
rose to $2.07 billion, or $2.79 per share, from $1.9 billion, or
$2.50 per share, a year ago.
Excluding special items, Amgen said it had adjusted earnings
of $3.15 per share. Analysts on average expected $3.00 per
share, according to Thomson Reuters I/B/E/S.
(Reporting by Bill Berkrot in New York; Editing by Matthew